INO compared with EQ: revenue, margins and what each company keeps, and the suppliers and customers both name

INOInovio Pharmaceuticals, Inc.

Mkt capRevenueRevenue

EQEquillium, Inc.

Mkt capRevenueRevenue

Compare

INOInovio Pharmaceuticals, Inc.

EQEquillium, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

INO1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±32.2%▲+16.90%×0.52

EQ1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±25.7%▲+17.41%×0.68

= impliedINO realized, solidEQ realized, hatchedOne scale, both sides: full bar = 33%× = |realized| ÷ impliedSource: market data

INOInovio Pharmaceuticals, Inc.

0.62▼−20.32%· post 2.05

Mkt cap$62.3MRevenue$65,343Q1 FY25Revenue—

EQEquillium, Inc.

1.38▼−2.90%· post 1.38

ClosedOct 30 '26

Mkt cap$86.9MRevenue$4MQ4 FY24Revenue$41MFY24

Compare

ClosedOct 30 '26

INOInovio Pharmaceuticals, Inc.

EQEquillium, Inc.

0.62▼−20.32%post 2.05

Price

1.38▼−2.90%post 1.38

$62.3M

Mkt cap

$86.9M

Q1 FY25$65,343

Revenue

$4MQ4 FY24

—

Revenue

$41MFY24

INO0.62▼−20.32%vsEQ1.38▼−2.90%ClosedOct 30 '26